Rebecca A. Tobin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rebecca A. Tobin has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Utkarsh J. Dang
Carleton University Ottawa Ontario Canada
2 shared publications - Alexandra Ahmet
Division of Endocrinology, Children's Hospital of Eastern Ontario and Department of Pediatrics University of Ottawa Ottawa Ontario Canada
1 shared publication - Eric P. Hoffman
ReveraGen BioPharma, Rockville, USA
1 shared publication - Heather MacDonald
Carleton University Ottawa Ontario Canada
1 shared publication - Leanne Marie Ward
Department of Pediatrics, University of Ottawa, Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario , Ottawa, ON
1 shared publication - Linda Johnson
TRiNDS LLC, Pittsburgh, PA
1 shared publication
Latest Publications
- Open Access
- 11 October 2026
- Published by Wiley in Clinical Endocrinology
Cortisol Cutoffs for Adrenal Insufficiency Using Elecsys II: A Systematic Review
Objective: Adrenal insufficiency (AI) is associated with increased risk of morbidity and mortality if improperly managed. Adrenocorticotrophin (ACTH) stimulation testing is the most widely used AI diagnostic test. Historically, a serum cortisol threshold of 500 nmol/L (18.1 µg/dL), derived using polyclonal assays, was widely used. Improved monoclonal immunoassays show reduced cross‐reactivity and lower cortisol values, but no universally accepted ACTH‐stimulated cortisol threshold exists. Suggestions ranging between 348 and 485 nmol/L [12.6–17.6 µg/dL] reflect methodology and cohort differences. Our objective was to systematically review the literature and recommend a revised cortisol threshold. Design and Methods: We searched MEDLINE, Web of Science, and Google Scholar for English language studies published between January 2016 and 19 September 2023 (PROSPERO CRD42023479405). Eligible studies reported original data, used the Roche Elecsys II assay, and recommended a cortisol threshold. Quality of evidence was assessed using the GRADE framework, and risk of bias with the ArRoWS questionnaire. Multiple suggested thresholds based on ROC, sensitivity/specificity, or regression analysis were identified. Results: Six studies involving 1799 samples from 430 adult and paediatric patients were included. A serum cortisol cutoff of 405 nmol/L (14.7 µg/dL) was defined based on synthesis, sensitivity analysis, and a conservative approach to reduce false‑negatives. Conclusions: We affirm recommendations to lower the cortisol threshold for AI when using monoclonal assays. A peak threshold of 405 nmol/L (14.7 µg/dL) is suggested for a standard‐dose ACTH test on the Elecsys II assay for diagnosis of AI, acknowledging limitations related to the small number and GRADE quality of included studies.
- 11 October 2026
- Published by Wiley in Clinical Endocrinology
Open AccessCortisol Cutoffs for Adrenal Insufficiency Using Elecsys II: A Systematic Review
Objective: Adrenal insufficiency (AI) is associated with increased risk of morbidity and mortality if improperly managed. Adrenocorticotrophin (ACTH) stimulation testing is the most widely used AI diagnostic test. Historically, a serum cortisol threshold of 500 nmol/L (18.1 µg/dL), derived using polyclonal assays, was widely used. Improved monoclonal immunoassays show reduced cross‐reactivity and lower cortisol values, but no universally accepted ACTH‐stimulated cortisol threshold exists. Suggestions ranging between 348 and 485 nmol/L [12.6–17.6 µg/dL] reflect methodology and cohort differences. Our objective was to systematically review the literature and recommend a revised cortisol threshold. Design and Methods: We searched MEDLINE, Web of Science, and Google Scholar for English language studies published between January 2016 and 19 September 2023 (PROSPERO CRD42023479405). Eligible studies reported original data, used the Roche Elecsys II assay, and recommended a cortisol threshold. Quality of evidence was assessed using the GRADE framework, and risk of bias with the ArRoWS questionnaire. Multiple suggested thresholds based on ROC, sensitivity/specificity, or regression analysis were identified. Results: Six studies involving 1799 samples from 430 adult and paediatric patients were included. A serum cortisol cutoff of 405 nmol/L (14.7 µg/dL) was defined based on synthesis, sensitivity analysis, and a conservative approach to reduce false‑negatives. Conclusions: We affirm recommendations to lower the cortisol threshold for AI when using monoclonal assays. A peak threshold of 405 nmol/L (14.7 µg/dL) is suggested for a standard‐dose ACTH test on the Elecsys II assay for diagnosis of AI, acknowledging limitations related to the small number and GRADE quality of included studies.
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200289
Test-Retest Reliability of Motor Function and Myometry Outcomes From the Vamorolone Trials in Duchenne Muscular Dystrophy
Understanding the reliability of outcomes used in clinical care and trials is important to delineate intervention-induced change from random variability. Reliability, sensitivity, and clinical meaningfulness of change are all key aspects of choosing the most appropriate outcome measure for a clinical trial. Common outcome measures to monitor progression and treatment effect in Duchenne muscular dystrophy (DMD) include measures of strength (myometry) and motor function tests: stand from supine velocity (STANDV), North Star Ambulatory Assessment (NSAA), 6-minute walk distance (6MWD), 10-m run/walk (RWV), and 4-stair climb velocity (CLIMBV). Our objective was to present test-retest reliability of common outcome measures using pretreatment measurements and to provide insights into missing measurements. Data were used on outcome measures in steroid-naïve, 4 to <7 years participants with DMD in 2 multisite, multicountry vamorolone trials (VBP15-002 [n = 48 participants] and VBP15-004 [n = 121 participants]). Bland-Altman analysis, the coefficient of variation, and the intraclass correlation coefficient (ICC) were used. Based on the ICC, NSAA, RWV, and CLIMBV have good reliability, whereas the 6MWD and STANDV have moderate reliability. Two different techniques were used for myometry in VBP15-002 (CINRG Quantitative Measurement System [CQMS]) and VBP15-004 (MicroFET2 handheld digital muscle dynamometer [HHD]). Reliability of myometry ranged from poor to moderate, and CQMS did not show improved reliability over HHD. The 6MWD and myometry showed the highest rates of missingness. Because of similar age ranges and harmonized outcomes, our findings were compared with the FOR-DMD cohort. Myometry and CLIMBV were not in FOR-DMD; reliability findings were concordant for the 4 outcomes in common. For most outcomes, we found reduced reliability compared with previous studies in older age groups. Reliable outcome measures, appropriate for the age of patients, are key to improving power in clinical trials, leading to fewer participants needed and reducing patient and site burden. We found NSAA, RWV, and CLIMBV to be the most reliable. This should be considered in the context of sensitivity to drug effect, and clinical meaningfulness of changes observed: all 5 motor outcomes were sensitive to drug effect of vamorolone and prednisone, whereas myometry was not.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200289
Open AccessTest-Retest Reliability of Motor Function and Myometry Outcomes From the Vamorolone Trials in Duchenne Muscular Dystrophy
Understanding the reliability of outcomes used in clinical care and trials is important to delineate intervention-induced change from random variability. Reliability, sensitivity, and clinical meaningfulness of change are all key aspects of choosing the most appropriate outcome measure for a clinical trial. Common outcome measures to monitor progression and treatment effect in Duchenne muscular dystrophy (DMD) include measures of strength (myometry) and motor function tests: stand from supine velocity (STANDV), North Star Ambulatory Assessment (NSAA), 6-minute walk distance (6MWD), 10-m run/walk (RWV), and 4-stair climb velocity (CLIMBV). Our objective was to present test-retest reliability of common outcome measures using pretreatment measurements and to provide insights into missing measurements. Data were used on outcome measures in steroid-naïve, 4 to <7 years participants with DMD in 2 multisite, multicountry vamorolone trials (VBP15-002 [n = 48 participants] and VBP15-004 [n = 121 participants]). Bland-Altman analysis, the coefficient of variation, and the intraclass correlation coefficient (ICC) were used. Based on the ICC, NSAA, RWV, and CLIMBV have good reliability, whereas the 6MWD and STANDV have moderate reliability. Two different techniques were used for myometry in VBP15-002 (CINRG Quantitative Measurement System [CQMS]) and VBP15-004 (MicroFET2 handheld digital muscle dynamometer [HHD]). Reliability of myometry ranged from poor to moderate, and CQMS did not show improved reliability over HHD. The 6MWD and myometry showed the highest rates of missingness. Because of similar age ranges and harmonized outcomes, our findings were compared with the FOR-DMD cohort. Myometry and CLIMBV were not in FOR-DMD; reliability findings were concordant for the 4 outcomes in common. For most outcomes, we found reduced reliability compared with previous studies in older age groups. Reliable outcome measures, appropriate for the age of patients, are key to improving power in clinical trials, leading to fewer participants needed and reducing patient and site burden. We found NSAA, RWV, and CLIMBV to be the most reliable. This should be considered in the context of sensitivity to drug effect, and clinical meaningfulness of changes observed: all 5 motor outcomes were sensitive to drug effect of vamorolone and prednisone, whereas myometry was not.